Annemiek van Ommen‐Nijhof

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Annemiek van Ommen‐Nijhof, Inge R. Konings, Clementine J.J. van Zeijl et al. · BMC Cancer · 2018 · 69 citations · Full text

Medicine, Oncology, Pharmacology +14

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Nature · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

Non-Motor Symptoms of Parkinson's Disease

Nico J. Weerkamp, Annemiek van Ommen‐Nijhof, Gerrit Tissingh · Oxford University Press eBooks · 2009 · 28 citations

Medicine, Neurology, Movement Disorders +13

Survival and prognostic factors in oligometastatic breast cancer

Annemiek van Ommen‐Nijhof, Tessa G. Steenbruggen, Laura Capel et al. · The Breast · 2022 · 14 citations · Full text

Medicine, Biostatistics, Oncology +15